Molecular Analysis of Disease Pathways

项目概要——总体 COBRE CMADP 成立于 2012 年 7 月，旨在鼓励基础研究科学家开发和实施 用于研究与疾病相关的生物途径和应用过程的新使能技术。结束 在过去的九年里，CMADP 研究人员一直在进行与分子分析相关的健康相关研究 的疾病途径。迄今为止，我们已通过研究支持和指导为 24 名初级教师提供了支持。的 迄今为止，已从该项目毕业的 18 名教师已获得超过 3850 万美元的外部资金。 我们还建立了三个新的核心实验室，专注于疾病研究的支持技术： 基因组测序核心、合成化学生物学核心和 KU 纳米加工设施（以前称为 微加工和微流体核心）。这三个核心带来了新的、重要的使能技术 到 KU，使我们能够吸引高素质的生物医学研究人员和教师到堪萨斯州。结果，CMADP 加强了该州生物医学研究的人力和物力资源。这个应用程序 请求为我们的 COBRE 中心第三阶段提供五年的资金，以实现以下目标：(1) 继续 培养一批新的和持续的研究人员，重点关注分子生物学这一非常广泛的主题 分析疾病途径，(2) 继续实施 COBRE 试点项目赠款的成功计划，该计划利用 我们的核心实验室，以及 (3) 通过扩大其能力和用户群来加强我们现有的核心实验室， 与 KU 研究办公室合作，根据以下组合将其定位为长期可持续发展 产生的费用加上大学的支持基础。结果将是一支非常强大的成功干部队伍 支持分子分析研究的职业中期生物医学研究人员和自我维持的核心实验室 全州范围内的疾病途径。我们坚信 CMADP 对生物医学研究的整体影响 因此，堪萨斯大学和堪萨斯州将变得充实而持久。

PROJECT SUMMARY – OVERALL The COBRE CMADP was created in July 2012 to encourage basic research scientists to develop and implement new enabling technologies for the study of biological pathways and applied processes related to disease. Over the past nine years, CMADP investigators have pursued health-related research related to the molecular analysis of disease pathways. We have supported 24 junior faculty to date through research support and mentoring. The 18 faculty that have graduated from the program thus far have generated over $38.5 million in external funding. We also established three new Core Laboratories focused on enabling technologies for the study of disease: the Genome Sequencing Core, the Synthetic Chemical Biology Core and the KU Nanofabrication Facility (formerly the Microfabrication & Microfluidics Core). These three Cores brought new and essential enabling technologies to KU, allowing us to attract high-quality biomedical researchers and faculty to Kansas. As a result, CMADP strengthened both the human and the physical resources for biomedical research in the state. This application requests five years of funding for Phase 3 of our COBRE Center to pursue the following objectives: (1) to continue growing a critical mass of new and continuing investigators focused on the very broad theme of molecular analysis of disease pathways, (2) to continue a successful program of COBRE Pilot Project grants that utilize our Core Labs, and (3) to strengthen our existing Core Labs by expanding their capabilities and user bases, working with the KU Office of Research to position them for long-term sustainability based on a combination of fees generated plus a base of support from the University. The result will be a very strong cadre of successful mid-career biomedical research faculty and self-sustaining Core Labs that support research in molecular analysis of disease pathways statewide. We strongly believe that the overall impact of CMADP on biomedical research at KU and the state of Kansas will thus be substantial and enduring.